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This study examined characteristics of HIV-infected patients in the TREAT Asia HIV Observational Database who were lost to
follow-up (LTFU) from treatment and care. Time from last clinic visit to 31 March 2009 was analysed to determine the interval
that best classiﬁed LTFU. Patients deﬁned as LTFU were then categorised into permanently LTFU (never returned) and temporary
LTFU (re-entered later), and these groups compared. A total of 3626 patients were included (71% male). No clinic visits for
180 days was the best-performing LTFU deﬁnition (sensitivity 90.6%, speciﬁcity 92.3%). During 7697 person-years of follow-up,
1648 episodes of LFTU were recorded (21.4 per 100-person-years). Patients LFTU were younger (P = 0.002), had HIV viral load
≥500copies/mL or missing (P = 0.021), had shorter history of HIV infection (P = 0.048), and received no, single- or double-
antiretroviral therapy, or a triple-drug regimen containing a protease inhibitor (P<0.001). 48% of patients LTFU never returned.
These patients were more likely to have low or missing haemoglobin (P<0.001), missing recent HIV viral load (P<0.001),
negative hepatitis C test (P = 0.025), and previous temporary LTFU episodes (P<0.001). Our analyses suggest that patients not
seen at a clinic for 180 days are at high risk of permanent LTFU, and should be aggressively traced.2 AIDS Research and Treatment
1.Introduction
Loss to followup (LTFU) in patients receiving antiretroviral
therapy can cause serious consequences such as discontinua-
tion of treatment and increased risk of death [1–3]. At a pro-
gram level, LTFU can make it diﬃcult to evaluate outcomes
of treatment and care [4, 5]. In resource-limited settings,
where treatment has become rapidly available following the
rollout of antiretroviral therapy, LTFU presents even more
challenging obstacles that require special consideration and
approaches [6, 7].
One of the key questions in patient followup is how to
deﬁneapatientasLTFU.Thishasvariedinstudiesconducted
in diﬀerent settings [8–10]. Deﬁning LTFU using a very early
threshold,forexample,apatientwithnoclinicvisitinthelast
three months, may result in many patients being considered
as LTFU who would return to clinic naturally at a later date.
Deﬁning LTFU with a long threshold, for example, one year,
maymeandelayingtoolongbeforeanyeﬀortismadetotrack
patients potentially at risk of LTFU.
The majority of research into LTFU in HIV-infected
patients receiving antiretroviral treatment in resource-
limited settings has been conducted in the sub-Saharan
Africa region [3, 10–13] .Af e ws t u d i e sh a v eb e e nc o n d u c t e d
among Asian, mostly female, patients [14–16]. Using
data from the TREAT Asia HIV Observational Database
(TAHOD), this study was carried out to ﬁnd the best-
performing deﬁnition of LTFU and examine the characteris-
tics of HIV-infected patients from the Asia-Paciﬁc who were
LTFU from treatment and care.
2. Methods
Established in 2003, TAHOD is a collaborative observational
cohort study involving 18 sites in the Asia-Paciﬁc region (see
Acknowledgement). Detailed methods have been published
previously [17]. Brieﬂy, each site recruited approximately
200–300 HIV-infected patients, with recruitment based on
a consecutive series of patients regularly attending a given
site from a particular start-up time. Ethical approval for the
study was obtained from the University of New South Wales
Ethics Committee, Western Institutional Review Board,
and respective local ethics committee from each TAHOD
participating site.
The following data were collected: patient demographics
and baseline data, CD4 and CD8 count, HIV viral load,
prior and new AIDS deﬁning illness (ADI), date and cause of
death, prior and current prescribed antiretroviral treatment
(ART), and reason for treatment change. Data were collected
according to a common protocol. Upon recruitment, all
available data prior to entry to TAHOD (considered as
retrospective data) were extracted from patient case notes.
Prospectivedatawereupdatedsix-monthly ateachclinic and
transferred to the data management centre for aggregation
and analyses in March and September each year. TAHOD
sites were encouraged to contact patients who have not been
seen in the clinics in the previous 12 months.
TAHOD data submitted at March 2009 and March 2010
were used to ﬁnd the best-performing deﬁnition of LTFU.
TAHOD patients who had no followup after recruitment
were not included in this analysis. Patients who were not
seen in clinic for more than 12 months prior to the March
2010 data submission (i.e., last clinic visit prior to March
2009) were considered to be truly LTFU. The days between
the last clinical visit and 31 March 2009 in the March 2009
data transfer were then used to ﬁnd the interval that best
classiﬁed a true LTFU in the following way. A series of
cutoﬀs were considered, from ten to 365 days, to deﬁne
patients as potentially LTFU. Each of these deﬁnitions of
potential LTFU was compared with the gold standard of true
LTFU, deﬁned as no patient followup in the 12 months prior
to 31 March 2010. The sensitivity and speciﬁcity of each
cutoﬀ in identifying true LTFU were calculated, and the best
performingcutoﬀidentiﬁedusingtheareaunderthereceiver
operator characteristic (ROC) curve. The optimal deﬁnition
of LTFU identiﬁed in terms of maximising the sensitivity
and speciﬁcity of true LTFU was found to be 180 days (see
Results). This deﬁnition was then used in the risk factor
analyses that follow.
Followup started from the last clinic visit at the March
2007 data submission. Patients who were considered LTFU
before March 2007 (i.e., had no clinic visits 180 days before
31March2007)wereexcludedfromtheanalysis.Forpatients
enrolled after March 2007, the followup started at the time of
enrolment. In terms of calculating person-years of followup,
the end of followup for patients who had no clinic visit for
180 days and so were considered as LTFU was deﬁned as 90
days after their last clinic visit. For patients not considered
LTFU, the end of followup was also deﬁned as 90 days after
their last clinic visit. If a patient died, the followup was
censored on the date of death if the date was within 180
days of their last clinic visit. Patients who died after March
2007wereconsideredtohavecompletefollowup.Itshouldbe
noted that patients who were considered LTFU could return
to clinic and reenter followup. The start of this reentry to
followup was deﬁned as 3 months prior to the ﬁrst clinic
visit that reinitiated followup. The patients that reentered
followup could also be re-LTFU if the patient subsequently
did not attend clinic for more than 180 days. The deﬁnitions
we adopted were consistent with those in a previous study
[18].
The rates of LTFU were calculated by the number of
total LTFU periods divided by the total duration of followup
contributed by the patients included in the analysis [18].
Because of the reentering and re-LTFU, patients could
contribute more than one episode of LTFU in this analysis.
Therateswerefurthercalculatedindiﬀerentstrata,including
age, sex, exposure category, hepatitis B and C infection, year
since HIV infection, calendar year, the latest CD4 count
and viral load, antiretroviral treatment status, CDC disease
stages, prophylaxis (coded as receiving or not), and haemo-
globin level, all taken at the start of each episode.
Factors associated with LTFU were assessed by multivari-
ate Poisson regression models, using generalised estimating
equations, to allow for multiple events of LTFU in the same
patients.CD4count,HIVviralload,antiretroviraltreatment,
AIDS diagnosis, and haemoglobin tests were included asAIDS Research and Treatment 3
Table 1: Receiver operating characteristic (ROC) analysis for the best-performing deﬁnition for loss to followup.
Cutoﬀ
(days) Sensitivity (%) Speciﬁcity (%) Area under
ROC Cutoﬀ (days) Sensitivity (%) Speciﬁcity (%) Area under
ROC
10 99.67 16.97 58.32 160 90.96 90.77 90.87
20 99.02 24.32 61.67 170 90.64 91.44 91.04
30 98.05 31.31 64.68 175 90.64 92.05 91.34
40 96.82 39.90 68.36 180 90.55 92.26 91.41
50 96.34 49.52 72.93 185 90.23 92.53 91.38
60 95.77 57.20 76.48 190 89.33 93.01 91.17
70 95.28 65.52 80.40 200 88.52 93.44 90.98
80 95.11 71.26 83.19 210 87.79 94.13 90.96
90 94.71 77.62 86.16 240 85.26 95.25 90.26
100 94.22 80.91 87.57 270 83.55 96.43 89.99
120 93.24 86.18 89.71 300 82.00 97.04 89.52
150 91.53 90.17 90.85 365 78.99 97.73 88.36
True LTFU deﬁned as no patient followup in the 12 month prior to 31 March 2010. Each cutoﬀ used as a potential deﬁnition of LTFU was the days between
last clinical visit and 31 March 2009 in the March 2009 data transfer. The sensitivity and speciﬁcity of each cutoﬀ in identifying true LTFU were calculated,
and the optimal cutoﬀ identiﬁed based on ROC analysis.
time-dependent variables and updated at the time the new
measurement or diagnosis was available.
Patients who had at least one episode of LTFU were
then categorised into two groups: those who had no more
clinical visits in the database (permanently LTFU) and those
who later reentered followup (temporary LTFU). Multivari-
ate logistic regression models were used to compare the
characteristics in patients who were considered permanently
LTFU with those who were temporary LTFU. All covariates
were taken at the end of the episode in patients with truly
LTFU or at the end of the ﬁrst episode in patients considered
temporary LTFU.
Multivariate models were built using a forward-stepwise
approach. The ﬁnal model included covariates that remained
signiﬁcantattheP<0.05level.Nonsigniﬁcantvariableswere
alsopresentedandadjustedfortheﬁnalmultivariatemodels.
Data management and statistical analyses were performed
using SAS for Windows (SAS Institute Inc., Cary, NC, USA)
and Stata (StataCorp, STATA 10.1 for Windows, College
Station, TX, USA).
3. Results
InMarch2007,therewere2565patientsinthedatabase.1061
patients were subsequently enrolled in TAHOD up to March
2010. A total of 3626 patients from TAHOD who had follow-
up visits in the clinic were included in this analysis. During
the study period (from March 2007 to March 2010), there
were 54 patients who died and considered to have complete
followup.
Using days between last clinic visit and 31 March 2009 in
the March 2009 data transfer, we identiﬁed the interval that
best classiﬁes a true LTFU (i.e., no clinic visit after 31 March
2009). An interval of 180 days was determined as the best-
performing deﬁnition (Table 1, sensitivity 90.6%, speciﬁcity
92.3%). Using 180 days as the LTFU cutoﬀ, during 7697
person-years of followup, a total of 1648 episodes of LTFU
from 1298 patients were identiﬁed, giving a crude LTFU rate
of 21.4 per 100 person-years (95% conﬁdence interval, CI,
20.4to22.5).Ofthose1648episodesofLTFUidentiﬁedusing
180 days as the cutoﬀ, 48% were considered permanently
LTFU (i.e., the patient did not return to clinic before 31
March 2010), corresponding to 45% of the 1298 patients.
The patient characteristics are summarised in Table 2.
The majority of patients were male (71%), aged between 36
and 45 years (40%), and reported heterosexual transmission
(64%). Chinese (27%), Thai (26%), and Indian (11%) were
the main ethnic groups. At recruitment, approximately 12%
didnothaveaCD4counttest,andofthosetested,themajor-
ity had a CD4 count more than 200cells/µL. Nearly half
(45%)didnothaveanHIVviralloadtest,andofthosetested,
the majority were below 500copies/mL. Close to half of the
patients (46%) were diagnosed with an AIDS deﬁning illness
atrecruitment,withtuberculosisbeingthemainillness.Most
patients (63%) had been reported to be diagnosed with HIV
for less than 6 years when recruited to TAHOD (measured
as the time from ﬁrst reported positive HIV test). Less than
10% of the patients were coinfected with either hepatitis B
or hepatitis C. At recruitment, the majority of patients had
normal haemoglobin level. At the start of study followup,
most of the patients were on antiretroviral therapy including
three or more drugs in combination including at least one
nucleoside reverse transcriptase inhibitor (NRTI) and one
nonnucleoside reverse transcriptase inhibitor. Over 20% of
patients were in a combination with at least one NRTI and a
proteaseinhibitor(PI).Allpatientswerereceiving,orstarted,
antiretroviral therapy during followup.
Table 3 summarises univariate and multivariate analyses
of factors associated with LTFU using 180 days as cut-oﬀ.I n
univariate analyses, the rate of LTFU was signiﬁcantly lower
in patients with a current CD4 counts above 200cells/µL
comparedtopatientswithaCD4countlessthan100cells/µL,
but this was not signiﬁcant in the ﬁnal multivariate model.
In the ﬁnal multivariate model (Table 3), factors associated4 AIDS Research and Treatment
Table 2: Patient characteristics.
Total 3626
Characteristics Number %
Sex
Male 2567 71
Female 1059 29
Current age (years)
≤35 1383 38
36–45 1449 40
46+ 794 22
Reported exposure
Heterosexual contact 2337 64
Homosexual contact 749 21
Injecting drug use 263 7
Other/unknown 277 8
Ethnicity
Chinese 989 27
Indian 390 11
Thai 933 26
Other/unknown 1314 36
Baseline CD4 count (cells/µl.)
≤100 239 7
101–200 406 11
201+ 2531 70
Missing 450 12
Baseline HIV RNA (copies/ml)
≤500 1482 41
501+ 379 10
Missing 1765 49
CDC disease stage at baseline
Stage A 1621 45
Stage B 321 9
Stage C 1684 46
Tuberculosis diagnosis at baseline
No 2758 76
Yes 868 24
Time since HIV infection (years)
≤5 2295 63
6+ 1246 34
Missing 85 2
Hepatitis B infection
No 2297 63
Yes 257 7
Not tested 1072 30
Hepatitis C infection
No 2007 55
Yes 324 9
Not tested 1295 36
Anemia at baseline
No 2480 68
Yes 597 16
Haemoglobin not tested 567 16
Table 2: Continued.
Total 3626
Characteristics Number %
Antiretroviral treatment at baseline
3 + (NRTI + NNRTI) 2224 61
3 + (NRTI + PI) 744 21
No/mono/double drug 583 16
3 + (other combination) 75 2
Anemia: haemoglobin <13g/dl (male), <11g/dl (female); NRTI: nucleoside
reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase
inhibitor; PI: protease inhibitor.
with LTFU included age (younger patients had higher rate
of LTFU), current HIV viral load (either patients with
HIV viral load ≥500 copies/mL or no tests in recent 180
days had higher rate of LTFU), history of HIV infection
(patients with shorter history of HIV infection had higher
rate of LTFU), hepatitis C infection (patients with positive
hepatitis C antibody had higher rate of LTFU), and, ﬁnally,
current combination of antiretroviral treatment (compared
topatientsontriple-drugregimenwithatleastoneNRTIand
one NNRTI, patients receiving no-, single-, or double-drug
antiretroviral therapy, or a triple-drug regimen containing at
least one NRTI and one PI, had higher rate of LTFU).
Table 4 shows factors that predict permanent LTFU
among patients who had no clinic visit for 180 days and so
met our optimal deﬁnition of LTFU. In the ﬁnal multivariate
model, patients permanently LTFU were more likely to be
older, have not been anemic, have no recent HIV viral load
test, have tested negative for hepatitis C infection or have
never tested for hepatitis C, and have had more than one
episode of previous temporary LTFU.
4. Discussion
We found that an interval of 180 days between clinic
visits was the best-performing deﬁnition of LTFU based
on sensitivity and speciﬁcity in identifying true LTFU. By
this deﬁnition, we observed that approximately one in ﬁve
patients in our cohort would miss clinic visits for more
than 180 days and so become deﬁned as LTFU. Among
these patients in our cohort close to half eventually returned
to followup, with half becoming truly lost to HIV-related
treatment and care.
The 180-day cutoﬀ has been used by other studies as
a working deﬁnition of LTFU [10, 19–21]. Other intervals
have also been proposed as measurements of classiﬁcations
o fL T F U ,s u c ha s9 0d a y s[ 8] and 365 days [9]. Regional- and
cohort-dependent characteristics, such as scheduled clinic
visits, patient burden, and drug availability could result in
speciﬁc intervals that best categorise patients at risk of LTFU.
Nevertheless, a 180-day (or 6-month) cutoﬀ is an appealing
and easy-to-apply deﬁnition that could be used in diﬀerent
clinical settings in the Asia-Paciﬁc region to ﬂag patients at
risk of being permanently lost to treatment and care. Our
analyses suggest patients with no clinic visits for six monthsAIDS Research and Treatment 5
Table 3: Factors associated with permanent or temporary LTFU, deﬁned as no clinic visit for 180 days, among all patients under followup.
Person-
years
Number
LTFU Crude Rate1
Adjusted
95% CI IRR2 95% CI P
value IRR2 95% CI P
value
Sex
Male 5468.1 1206 22.06 (20.85, 23.34) 1.00 1.00
Female 2229.2 442 19.83 (18.06, 21.77) 1.10 (0.98, 1.24) 0.090 1.04 (0.93, 1.17) 0.446
Current age (years)
≤35 2210.4 575 26.01 (23.97, 28.23) 1.00 1.00 0.0023
36∼45 3320.2 718 21.62 (20.10, 23.27) 0.82 (0.74, 0.92) 0.001 0.89 (0.79, 1.00) 0.050
46+ 2166.6 355 16.39 (14.77, 18.18) 0.69 (0.60, 0.79) <0.001 0.76 (0.66, 0.88) <0.001
Reported exposure
Heterosexual
contact 5144.5 985 19.15 (17.99, 20.38) 1.00 1.00
Homosexual
contact 1707.2 344 20.15 (18.13, 22.40) 1.10 (0.93, 1.29) 0.275 1.05 (0.89, 1.25) 0.540
Injecting drug use 344.3 125 36.31 (30.47, 43.27) 1.21 (0.97, 1.51) 0.098 1.10 (0.86, 1.40) 0.437
Other/unknown 501.3 194 38.70 (33.62, 44.55) 1.64 (1.37, 1.98) <0.001 1.56 (1.29, 1.88) <0.001
Current CD4 count (cells/µl.)
≤100 233.7 69 29.52 (23.32, 37.38) 1.00 1.00
101–200 635.7 136 21.40 (18.09, 25.31) 0.92 (0.68, 1.22) 0.551 0.96 (0.72, 1.29) 0.800
201+ 6327.6 1181 18.66 (17.63, 19.76) 0.75 (0.58, 0.96) 0.023 0.79 (0.61, 1.02) 0.071
Missing 500.3 262 52.37 (46.40, 59.11) 1.18 (0.90, 1.55) 0.235 0.99 (0.74, 1.31) 0.922
Current HIV RNA (copies/ml)
≤500 4213.7 679 16.11 (14.95, 17.37) 1.00 1.00 0.0213
501+ 537.1 158 29.42 (25.17, 34.38) 1.71 (1.43, 2.04) <0.001 1.24 (1.03, 1.51) 0.026
Missing 2946.4 811 27.52 (25.69, 29.49) 1.75 (1.55, 1.98) <0.001 1.64 (1.45, 1.86) <0.001
CDC disease stage
Stage A 3205.1 828 25.83 (24.13, 27.65) 1.00 1.00
Stage B 801.6 118 14.72 (12.29, 17.63) 0.93 (0.76, 1.14) 0.507 0.95 (0.77, 1.17) 0.623
Stage C 3690.5 702 19.02 (17.67, 20.48) 0.84 (0.75, 0.93) 0.001 0.92 (0.82, 1.02) 0.125
Tuberculosis diagnosis
Yes 1806.7 372 20.59 (18.60, 22.79) 1.00 1.00
No 5890.6 1276 21.66 (20.51, 22.88) 1.04 (0.92, 1.18) 0.537 0.98 (0.87, 1.12) 0.801
Time since HIV infection (years)
≤5 3477.2 785 22.58 (21.05, 24.21) 1.00 1.00 0.0053
6+ 4115.7 844 20.51 (19.17, 21.94) 0.84 (0.75, 0.94) 0.002 0.89 (0.79, 1.00) 0.048
Missing 104.3 19 18.21 (11.61, 28.55) 0.58 (0.36, 0.94) 0.027 0.49 (0.30, 0.79) 0.004
Hepatitis B infection
Yes 584.5 112 19.16 (15.92, 23.06) 1.00 1.00
No 5101.9 883 17.31 (16.20, 18.49) 0.93 (0.76, 1.13) 0.474 0.90 (0.74, 1.10) 0.319
N/A 2010.8 653 32.48 (30.08, 35.06) 0.98 (0.80, 1.21) 0.859 1.07 (0.85, 1.35) 0.548
Hepatitis C infection
Yes 541.4 149 27.52 (23.44, 32.31) 1.00 1.00 0.0303
No 4692.8 796 16.96 (15.82, 18.18) 0.81 (0.67, 0.98) 0.029 0.81 (0.67, 0.98) 0.034
N/A 2463.0 703 28.54 (26.51, 30.73) 0.75 (0.62, 0.91) 0.004 0.77 (0.63, 0.93) 0.008
Current anemia (male < 13g/dl, female < 11g/dl)
Yes 1021.1 155 15.18 (12.97, 17.77) 1.00 1.00
No 5771.6 1157 20.05 (18.92, 21.24) 1.09 (0.92, 1.30) 0.302 1.11 (0.94, 1.32) 0.227
N/A 904.5 336 37.15 (33.38, 41.34) 1.31 (1.07, 1.59) 0.008 1.09 (0.89, 1.34) 0.3826 AIDS Research and Treatment
Table 3: Continued.
Person-
years
Number
LTFU Crude Rate1
Adjusted
95% CI IRR2 95% CI P
value IRR2 95% CI P
value
Current ART4
3 + (NRTNRTI) 4830.8 942 19.50 (18.29, 20.79) 1.00 1.00 0.0013
3 + (NRTI + PI) 1898.3 377 19.86 (17.95, 21.97) 1.21 (1.06, 1.38) 0.005 1.22 (1.07, 1.39) 0.003
No/mono/double
ARV 762.7 300 39.33 (35.12, 44.05) 2.18 (1.90,2.50) <0.001 1.92 (1.66, 2.22) <0.001
3+( o t h e r
combination) 205.4 29 14.12 (9.81, 20.32) 0.95 (0.65, 1.38) 0.786 1.01 (0.69, 1.47) 0.975
(1) Crude rate, per 100 person-years.
(2) Stratiﬁed by TAHOD sites.
(3) Overall for test for trend (ordinal categorical covariates) or for homogeneity (nominal categorical covariates).
(4) ART: NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
are at high risk of being permanently lost and should be
aggressively traced.
Chi et al. also found that a cutoﬀ of 180 days was
optimal to deﬁne LTFU after analysing data from the Africa,
Asia, and Latin America regions of the IeDEA collaboration
(including data from our cohort) [22]. There are some
methodological diﬀerences between our analyses, principally
regarding minimum numbers of patients for site inclusion.
Chi et al. found quite extensive heterogeneity between sites,
something we also found to a lesser extent. However, it
is nevertheless reassuring that we found a similar optimal
cutoﬀ of 180 days without clinic visits to deﬁne LTFU. With
rapid scaling up of antiretroviral treatment taking place
globally, there is a need to adopt a universal consistent
deﬁnition of LTFU, or a general algorithm to deﬁne cutoﬀs,
to evaluate HIV treatment programs in diﬀerent regions
[6, 7, 19].
Over one in ﬁve patients in our cohort failed to come
to clinic for more than 180 days in a given year. Similar
rates have also been found in patients from Africa [3, 11].
However, the LTFU rate was lower in EuroSIDA [23] ,al a r g e
prospective cohort study with HIV-infected patients mainly
from Europe (using one year as a cutoﬀ). Approximately half
ofthepatientswhoexperiencedLTFUinourstudylatercame
back to clinic, and patients who had a previous episode of
LTFU were more likely to prove to be true LTFU, similar to
previous ﬁndings [18].
We found that younger patients, patients infected with
hepatitis C, and patients with detectable or unmeasured viral
load were more likely to experience LTFU. These ﬁndings
are all consistent with previous study ﬁndings [10, 11, 24–
26]. Patients with undetectable viral load are likely to be
motivated and adherent to antiretroviral treatment and thus
remain in care. Among those patients who experienced
LTFU, we found that those who tested negative for hepatitis
C infection or were never tested for hepatitis C were more
likely to be permanently LTFU. This ﬁnding seems coun-
terintuitive, but it might be that patients who have tested
positive for hepatitis C receive more medical attention from
their clinicians and thus prove less likely to be permanently
LTFU. Among patients identiﬁed as LTFU, anemic patients
were also more likely to be permanently lost to treatment
and care. Anemia has been shown to be a strong prognostic
marker for HIV disease progression and survival [27], which
could, at least in part, explain these patients failing to return
to followup.
Compared to patients on NNRTI-based regimen,
patients receiving no-, single-, or double-drug antiretroviral
therapy or a triple-drug regimen containing PI were more
likely to experience LTFU. The reasons for this are not clear.
Thegreaterlosstofollowupmaybeassociatedwithincreased
drug toxicity, either resulting in a patient receiving mono- or
dual therapy or from receiving a PI. Patients receiving PI-
based regimens are also those who are more likely to be on
a second line regimen, a regimen that may be substantially
more expensive than ﬁrst line. In the Asia Paciﬁc region,
out-of-pocket expenses are needed to pay for treatment in
some clinics. Hence, the lost to followup may be associated
with drug availability or aﬀordability. It is worth noting that
patients receiving mono- or dual therapy, or a PI based
regimen, were also associated with being less likely to be
permanently lost to followup, that is to say more likely to
return to clinic (albeit not quite statistically signiﬁcantly
so). This possibly supports the idea of these regimens being
associated with short-term drug availability or aﬀordability
issues. Unfortunately, data are not available to address this
issue in any greater detail.
It has been shown that, in resource-limited settings,
predominantlyinAfrica,patientswhoareLTFUhaveamuch
poorer prognosis than patients who remain in followup
[5]. In part, this is due to a proportion of patients who
die not having vital status information updated at their
treatment site. The extent to which this occurs in TAHOD
is uncertain. While it seems likely that at least some patients
who are LTFU have died without this information reaching
the site, the lack of association between key measures of HIV
disease progression, such as CD4 count and AIDS deﬁning
illnesses, and LFTU suggests it may be lower than in African
settings. However, this association between LTFU and poorer
prognosis underpins the need for consistent deﬁnitions ofAIDS Research and Treatment 7
Table 4: Factors that predict permanent LTFU in patients without a clinic visit for 180 days.
Number True loss % OR1 95% CI P value Adjusted OR1 95% CI P value
Sex
Male 1206 584 48.4 1.00 1.00
Female 442 209 47.3 0.89 (0.69, 1.15) 0.359 0.80 (0.61, 1.05) 0.104
Current age (years)
≤35 568 278 48.9 1.00 1.00 0.0972
36∼45 717 340 47.4 1.33 (1.03, 1.71) 0.031 1.31 (1.00, 1.72) 0.050
46+ 363 175 48.2 1.27 (0.94, 1.72) 0.118 1.28 (0.93, 1.77) 0.128
Reported exposure
Heterosexual contact 985 443 45.0 1.00 1.00
Homosexual contact 344 199 57.8 1.12 (0.78, 1.60) 0.532 1.24 (0.85,1.81) 0.262
Injecting drug use 125 55 44.0 1.01 (0.59, 1.73) 0.969 1.32 (0.72, 2.41) 0.364
Other/unknown 194 96 49.5 1.07 (0.69, 1.64) 0.773 1.22 (0.78, 1.93) 0.382
Current CD4 count (cells/µl.)
≤100 58 36 62.1 1.00 1.00
101–200 129 66 51.2 0.76 (0.36, 1.60) 0.471 0.99 (0.47, 2.13) 0.989
201+ 1068 465 43.5 0.62 (0.33, 1.18) 0.144 0.82 (0.42, 1.59) 0.551
Missing 393 226 57.5 1.50 (0.77, 2.93) 0.238 1.18 (0.58, 2.42) 0.649
Current HIV RNA (copies/mL)
≤500 598 230 38.5 1.00 1.00 0.0112
501+ 153 78 51.0 1.02 (0.68, 1.52) 0.924 0.94 (0.62, 1.42) 0.767
Missing 897 485 54.1 2.13 (1.63, 2.80) <0.001 1.54 (1.13, 2.09) 0.006
CDC disease stage
Stage A 828 413 49.9 1.00 1.00
Stage B 121 54 44.6 0.77 (0.48, 1.22) 0.258 0.70 (0.43, 1.14) 0.154
Stage C 699 326 46.6 1.00 (0.78, 1.27) 0.975 1.05 (0.81, 1.36) 0.702
Tuberculosis diagnosis
Yes 361 186 51.5 1.00 1.00
No 1287 607 47.2 0.87 (0.66, 1.16) 0.342 0.85 (0.63, 1.15) 0.297
Time since HIV infection (years)
≤5 771 400 51.9 1.00 1.00
6+ 858 389 45.3 1.25 (0.98, 1.60) 0.076 1.03 (0.79, 1.34) 0.835
Missing 19 4 21.1 0.37 (0.12, 1.17) 0.091 0.43 (0.13, 1.43) 0.170
Hepatitis B infection
Yes 112 47 42.0 1.00 1.00
No 883 431 48.8 1.30 (0.84, 2.03) 0.243 1.35 (0.84, 2.16) 0.222
N/A 653 315 48.2 1.31 (0.82, 2.09) 0.253 1.03 (0.60,1.76) 0.908
Hepatitis C infection
Yes 149 66 44.3 1.00 1.00 0.0042
No 796 376 47.2 1.57 (1.01, 2.45) 0.046 1.66 (1.04, 2.66) 0.034
N/A 703 351 49.9 1.96 (1.26, 3.05) 0.003 2.16 (1.35, 3.46) 0.001
Current anemia (male < 13g/dL, female < 11g/dL)
Yes 141 87 61.7 1.00 1.00 <0.0012
No 1065 456 42.8 0.53 (0.35, 0.81) 0.003 0.50 (0.32, 0.76) 0.001
N/A 442 250 56.6 1.15 (0.73, 1.81) 0.549 0.78 (0.49, 1.26) 0.310
Current ART∗∗
3 + (NRTI + NNRTI) 911 404 44.3 1.00 1.00
3 + (NRTI + PI) 356 167 46.9 0.76 (0.57, 1.02) 0.072 0.74 (0.54,1.01) 0.057
No/mono/double ARV 352 209 59.4 0.93 (0.69, 1.26) 0.644 0.78 (0.57, 1.08) 0.137
3 + (other combination) 29 13 44.8 0.89 (0.40, 1.98) 0.770 0.85 (0.38, 1.94) 0.7078 AIDS Research and Treatment
Table 4: Continued.
Number True loss % OR1 95% CI P value Adjusted OR1 95% CI P value
Previous episode of temporary LTFU
None 1298 589 45.4 1.00 1.00 <0.0012
Once 296 158 53.4 2.79 (2.05, 3.80) <0.001 2.71 (1.97, 3.72) <0.001
Twice 54 46 85.2 31.76 (13.91, 72.52) <0.001 27.75 (12.03, 64.01) <0.001
(1) Stratiﬁed by TAHOD sites.
(2) Overall for test for trend (ordinal categorical covariates) or for homogeneity (nominal categorical covariates).
(3) ART: NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
LTFUinresearchcohortstudies,andwheretherearepossible
active patient tracing strategies or at least sampling-based
approaches [28] to ensure comparability of results across
studies and settings.
Several limitations should be considered in interpreting
the results in this paper. First, TAHOD participating sites are
generally urban referral centres, and the patients recruited in
TAHOD were those regularly attending a given TAHOD site.
Hence, TAHOD patients are not representative of all HIV-
infected patients in the Asia and Paciﬁc region. The overall
rate of LTFU we saw in our study is therefore likely to be
an underestimate of rates across the region. However, the
eﬀect of these sampling biases on the optimal deﬁnition of
LTFU and on the covariate analyses is arguably less strong.
It is reassuring that our estimate of the optimal deﬁnition
of LTFU is consistent with that seen across Africa and Latin
America [22]. Second, since antiretroviral treatment has
become more decentralised and available in distant or rural
communities with rapid scale-up programs, patients might
choose to receive treatment and care locally rather than at
tertiary and referral centres [29, 30]. Consequently, patients
may have been retained in care but not necessarily in the
clinics involved in this study. Information on referral to
other health facility was only recently included in the data
collection, so we could not further verify if patients were
retained in care or truly loss to health services. Third, we
do not collect data on the measures TAHOD sites undertake
to routinely trace patients who are LTFU. These measures
diﬀer across sites according to local practices and conditions.
Eﬀective patient tracking and recording are essential to
program evaluation and maintenance of treatment and care
[1, 18]. What patient tracking measures are eﬀective in
retaining patients in treatment and care in the Asia-Paciﬁc
region is an area that deserves further research. We also do
not have data on transportation [31], social and economic
status [32], pregnancy for women [10], and community
support [33], all of which have been found to be important
determinants of LTFU. Lastly, the patients included in this
study were all receiving, or started, antiretroviral treatment
and had clinical assessments. Consequently, the results
cannot be extrapolated to patients not yet initiated on
antiretroviral therapy. Research into followup among HIV-
infected patients not receiving antiretroviral treatment in
the Asia-Paciﬁc region needs to be considered [34–36],
particularly in the context of the move to start treatment
earlier.
5. Conclusion
With rapid scaleup of antiretroviral treatment, it is essential
to study factors that predict loss to followup and identify
patients at risk of loss to treatment and care, particularly
in resource-limited settings. At the treatment and care level,
this can maintain eﬃcacy of antiretroviral therapy and avoid
adverse events. At the program evaluation level, the impact
of loss to followup on overall treatment outcome, disease
progression, and survival can then be accounted for with
appropriate statistical adjustments. Collaboration with HIV
treatment programs in other regions in studies on LTFU and
inparticularstandardisationofLTFUdeﬁnitionsareessential
for reporting and program evaluation.
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